图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
肿瘤形成评论综述™
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN 打印: 0893-9675
ISSN 在线: 2162-6448

肿瘤形成评论综述™

DOI: 10.1615/CritRevOncog.2016016120
pages 125-139

Circulating Tumor Cells in Breast Cancer Patients

Carolyn Hall
The University of Texas M.D. Anderson Cancer Center, Department of Surgical Oncology, Houston, Texas
Lily Valad
The University of Texas M.D. Anderson Cancer Center, Department of Surgical Oncology, Houston, Texas
Anthony Lucci
The University of Texas M.D. Anderson Cancer Center, Department of Surgical Oncology, Houston, Texas

ABSTRACT

Breast cancer is the most commonly diagnosed cancer among women, resulting in an estimated 40,000 deaths in 2014.1 Metastasis, a complex, multi-step process, remains the primary cause of death for these patients. Although the mechanisms involved in metastasis have not been fully elucidated, considerable evidence suggests that metastatic spread is mediated by rare cells within the heterogeneous primary tumor that acquire the ability to invade into the bloodstream. In the bloodstream, they can travel to distant sites, sometimes remaining undetected and in a quiescent state for an extended period of time before they establish distant metastases in the bone, lung, liver, or brain. These occult micrometastatic cells (circulating tumor cells, CTCs) are rare, yet their prognostic significance has been demonstrated in both metastatic and non-metastatic breast cancer patients. Because repeated tumor tissue collection is typically not feasible and peripheral blood draws are minimally invasive, serial CTC enumeration might provide "real-time liquid biopsy" snapshots that could be used to identify early-stage breast cancer patients with micrometastatic disease who are at risk for disease progression and monitor treatment response in patients with advanced disease. In addition, characterizing CTCs might aid in the development of novel, personalized therapies aimed at eliminating micrometastases. This review describes current CTC isolation, detection, and characterization strategies in operable breast cancer.


Articles with similar content:

Revolutionary Advances in the Diagnosis and Treatment of Familial Adenomatous Polyposis
Journal of Environmental Pathology, Toxicology and Oncology, Vol.28, 2009, issue 1
William B. Long III, Richard Edlich, Margot E. Chase, Catherine L. Cross, Courtney A. Wack, K. Dean Gubler
On the Origin of Cancer Metastasis
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 1 - 2
Thomas N. Seyfried, Leanne C. Huysentruyt
Novel Approaches for Colon Cancer Prevention by Cyclooxygenase-2 Inhibitors
Journal of Environmental Pathology, Toxicology and Oncology, Vol.21, 2002, issue 2
Bandaru S. Reddy, Chinthalapally V. Rao
Liquid Biopsies for Assessing Metastatic Melanoma Progression
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 1-2
Dave S.B. Hoon, Kelly Huynh
Genetic Alterations in Liver Carcinogenesis: Implications for New Preventive and Therapeutic Strategies
Critical Reviews™ in Oncogenesis, Vol.11, 2000, issue 1
Francesco Feo, Maria R. De Miglio, Rosa M. Pascale, Maria M. Simile, Diego Calvisi, Maria R. Muroni